Compare KOPN & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KOPN | ASMB |
|---|---|---|
| Founded | 1984 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 396.8M | 442.9M |
| IPO Year | 2025 | 2010 |
| Metric | KOPN | ASMB |
|---|---|---|
| Price | $5.08 | $28.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $4.69 | ★ $44.20 |
| AVG Volume (30 Days) | ★ 11.6M | 119.0K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 103.03 | 91.78 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,530,311.00 | N/A |
| Revenue This Year | $50.07 | N/A |
| Revenue Next Year | $33.33 | $638.39 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 46.53 | N/A |
| 52 Week Low | $1.23 | $13.13 |
| 52 Week High | $6.45 | $39.71 |
| Indicator | KOPN | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 62.85 | 48.14 |
| Support Level | $2.05 | $26.50 |
| Resistance Level | N/A | $30.58 |
| Average True Range (ATR) | 0.68 | 1.66 |
| MACD | 0.03 | 0.14 |
| Stochastic Oscillator | 54.19 | 43.76 |
Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.